Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Exemestane beats tamoxifen in first phase III head to head trial in advanced breast cancer

18.03.2004


The first results from the world’s only phase III trial to compare tamoxifen with the newer hormone treatment exemestane in advanced breast cancer shows that exemestane is safe, superior and lengthens progression-free survival.



The median progression-free survival for patients taking exemestane was 10.9 months compared with 6.7 months for those taking tamoxifen. Complete and partial response rates were also higher in the exemestane arm with 7.4% responding completely and 36.8% partially, compared to 2.6% of tamoxifen patients completely responding and 26.6% partially responding.

Dr Robert Paridaens will tell delegates at the 4th European Breast Cancer Conference today (Thursday 18 March) that the drug would be a good choice for first line treatment in hormone responsive metastatic breast cancer and that its safety profile meant it was also an attractive proposition for use as an adjuvant drug or to prevent breast cancer in high risk women. In Europe, it is currently licensed for use only in metastatic breast cancer that has recurred after, or during, tamoxifen treatment.


The majority of breast cancers in postmenopausal women rely on female hormones to grow. Exemestane is a steroidal aromatase inhibitor (SAI); it permanently inactivates aromatase, the enzyme that converts androgens into oestrogens in postmenopausal women. So, the effect of the drug is to deprive breast cancer cells of oestrogen.

Dr Paridaens, a medical oncologist at the University Hospital Gasthuisberg in Leuven, Belgium, said the trial was initiated as a phase II with the possibility of extending to phase III if results were promising. Phase III has involved 382 patients from 81 centres in 25 countries. It was an ’open label’ study i.e. both doctors and patient knew which drug was being administered after patients were randomised to the tamoxifen or exemestane arm. The primary objective was to identify whether exemestane would produce an increase of three months progression-free survival over tamoxifen. It also aimed to establish the safety of the drug.

Said Dr Paridaens: "The main endpoint of treatment in advanced disease is control of symptoms – in other words, progression free survival with the fewest possible side effects as qualify of life in incurable disease is essential. Aromatase inhibitors do induce hot flushes and menopausal symptoms like tamoxifen does and they may elicit more muscular and joint aches. But they produce less thromboembolic (clotting) events than tamoxifen and unlike tamoxifen they avoid a risk of endometrial cancer."

One interesting finding in the study, according to Dr Paridaens, was that there was no adverse effect on patients’ lipid profiles, contrary to what has been seen in studies of non-steroidal aromatase inhibitors (NSAIs). "We don’t know yet whether that will translate in the long term into greater cardiovascular safety or not, or whether it would be an indication for use in women with dyslipidemia (abnormal lipid measurements). That remains to be demonstrated in clinical studies."

He said there were many questions still to be answered in future trials – for example, can steroidal and non-steroidal aromatase inhibitors (AIs) safely be combined with chemotherapy; what effect does exemestane have on the bones, and can resistance to treatment be delayed by use of other drugs such as HER pathway blockers? Numerous trials were underway looking at AIs as adjuvant treatment. It was possible that sequential treatments with anti-oestrogens and AIs will turn out to be the best solution, but if so, in which sequence and for how long would also have to be determined. "A door that has been opened shows numerous other doors to be explored," he said.

He concluded: "Accrual to our trial was slow because the inclusion criteria were strict and there were other trials running at the same time, so I am really grateful for the patients and for the centres that participated and made it possible for us to get a clear answer on our primary objective of progression-free survival."


Note: The study was sponsored by Pfizer (formerly Pharmacia at start of the trial), who supplied Exemestane and covered the costs of study monitoring, data management at participating centres and data processing at the EORTC data centre.

Margaret Willson | EurekAlert!
Further information:
http://www.fecs.be/

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

Im Focus: Quantum-physical Model System

Computer-assisted methods aid Heidelberg physicists in reproducing experiment with ultracold atoms

Two researchers at Heidelberg University have developed a model system that enables a better understanding of the processes in a quantum-physical experiment...

Im Focus: Glacier bacteria’s contribution to carbon cycling

Glaciers might seem rather inhospitable environments. However, they are home to a diverse and vibrant microbial community. It’s becoming increasingly clear that they play a bigger role in the carbon cycle than previously thought.

A new study, now published in the journal Nature Geoscience, shows how microbial communities in melting glaciers contribute to the Earth’s carbon cycle, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

New quantum liquid crystals may play role in future of computers

21.04.2017 | Physics and Astronomy

A promising target for kidney fibrosis

21.04.2017 | Health and Medicine

Light rays from a supernova bent by the curvature of space-time around a galaxy

21.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>